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OBJECTIVE: To evaluate the effects of estrogen treatment in combination with gestrinone on an experimental rat model of 
endometriosis. 
METHODS: Uterine transplants were attached to the peritoneum of female Wistar rats via a surgical autotransplantation technique. 
The implanted area was measured during the proestrus phase and after hormonal treatment. We performed morphometric analysis 
and examined the macroscopic and morphometric alterations of endometrial implants after hormonal treatment in ovariectomized 
rats. 
RESULTS: The high dose of estrogen caused macroscopic increases in the endometrial implant group compared with other groups, 
which were similar to increases in the proestrus phase. The low dose showed morphometric development of implants, such as an 
increase in number of endometrial glands, leukocyte infiltration and mitosis. Gestrinone antagonized both doses of estrogen. 
CONCLUSION: Our findings suggest that gestrinone antagonizes estrogen’s effects on rat peritoneal endometrial implants.
KEYWORDS: Experimental endometriosis. Peritoneal implants. Ovariectomized rats. Gestrinone. Estrogen.
INTRODUCTION
Endometriosis is a clinical and pathological entity 
that was initially described by Rokitanski in 1860.1 
Endometriosis is characterized by the presence, outside the 
uterine cavity, of tissue resembling functioning endometrial 
glands and stroma. Sampson was responsible for the 
classification of this affliction as a non-neoplasic disease in 
1925.2 In fact, endometriosis is one of the most enigmatic 
and problematic maladies affecting women of reproductive 
age. It is associated with pain and infertility. Although it is 
not a malignant disorder, endometriosis exhibits cellular 
proliferation, cellular invasion and neoangiogenesis.3 
Endometriosis is most commonly observed over visceral 
and peritoneal surfaces within the female pelvis. Despite 
being one of the most frequently encountered gynecological 
diseases, the pathophysiology of this disease remains 
poorly understood.4 In addition, ethical considerations limit 
options for controlled experiments, and it is not possible 
to monitor the disease progression without performing 
repeated laparoscopies. Thus, research into the fundamental 
mechanisms (e.g. mechanisms by which menstrual 
endometrium adheres, invades and establishes a functional 
vasculature to persist in an ectopic site), as well as into new 
therapeutic approaches, is best performed in experimental 
animal models.5
Because menstrual shedding is a requirement for the 
spontaneous development of this disease, endometriosis 
occurs naturally only in humans and some non-human 
primates. Non-human primates have been extensively used 
for the investigation of endometriosis; however, the very 526
CLINICS 2008;64:525-30 Does gestrinone antagonize the effects of estrogen on endometrial implants upon the peritoneum of rats?
Lobo VLR et al.
high costs of animal handling limit the use of primates as an 
experimental model. For this reason, experimental models 
for endometriosis have recently been developed in small 
laboratory animals, especially rodents, by the transplantation 
of pieces of endometrial tissue to ectopic sites.5
Endometriosis in rats can be induced by transplanting 
endometrial tissue to ectopic sites. These models are 
classified into two types, homologous and heterologous 
models. Homologous models have been employed using 
the surgical transplantation of endometrium of the same or 
syngeneic animals, whereas in heterologous models, human 
endometrial fragments are transferred either intraperitoneally 
or subcutaneously to immunodeficient mice.5
Autotransplantation of uterine tissue to ectopic sites of 
small laboratory animals has been established not only in 
rats,6-8 but also in other models.9,10 Of these non-primate 
models, mainly the rat and mouse models have been 
extensively developed in recent years. In these models 
of endometriosis, uteri are removed and cut into small 
pieces, which are then reintroduced, mostly by suturing, 
into the peritoneal cavity. In most of these studies, the 
endometrium was not separated from myometrium; thus, 
both compartments were implanted.9 In the rat, the uterine 
tissue develops into fluid-filled, ovoid, cystic structures 
composed of myometrial and endometrial tissue. The cysts 
grow but stabilize in size by two months and remain viable 
for at least ten months.11Autotransplanted uterine tissue in 
the rodent model shows steroid hormone dependency, and 
thus, this model has been widely used for determining the 
responsiveness of ectopic lesions to steroid hormones as well 
as to drugs interfering with steroid action. Comparable to the 
situation in humans, the growth of the ectopic endometrial 
tissue in both rodent species was shown to be estrogen-
dependent.10,11 In rats that were ovariectomized three weeks 
after engrafts of uterine tissue, the ectopic fragments 
recovered much better in animals treated with estrogen alone 
after ovariectomy than in those with combined estrogen and 
progesterone treatment.12 Fang et al. (2004)13 confirmed 
the important role for estrogen as a factor determining 
the size of the implants in mice and demonstrated that the 
anti-proliferative effect of progesterone on the estrogen-
dependent growth of endometrial tissue is mediated by 
an intact progesterone receptor, because this estrogen-
dependent growth could be suppressed by progesterone in 
uterine tissues of wild-type, but not of progesterone receptor-
deficient mice.
Similar to the situation in humans, the regression 
of uterine ectopic implants could be induced in rats by 
generating a hypoestrogenic state, for example, by the 
application of GnRH agonists,14 by synthetic progestational 
compounds such as levonorgestrel or dienogest15,16 or by 
danazol treatment.17 Similar effects could be achieved in 
this model by reducing the estrogen concentration by the 
application of anti-estrogens, by using the selective estrogen 
receptor modulator raloxifen,18 by treatment with aromatase 
inhibitors that interfere with estrogen synthesis, or by 
ovariectomy.14 
Various authors have reported many complications and 
side effects of the hormone therapy (HT) on postmenopausal 
women.19,20 In addition, there is a risk of endometriosis 
recurrence in ovariectomized women who have had 
peritoneal endometriosis and received estrogen replacement.19 
Therefore, this hormone should be administered with 
progestagen to avoid this risk. 
Gestrinone, a progestagen (tri-enic steroid) with 
antiestrogen  properties,  presents  good  results  for 
endometriosis treatment during menarche.21 Few studies 
have evaluated gestrinone in animal models. Some of these 
were done in rabbits22,23 and one report used gestrinone in 
rats with intact ovaries.24 Yet, the effectiveness of this drug 
with an exogenous low or conventional dose of estrogen 
remains unclear. Thus, the aim of this study was to evaluate 
the gestrinone-with-estrogen effects on endometrial implants 
in ovariectomized rats.
MATERIAL AND METHODS
One hundred and forty rats (Rattus norvegicus albinus) 
of the EPM-1 Wistar strain at 3 months of age were used, 
and their average weight was 200 grams. The animals were 
supplied by the Center for the Development of Experimental 
Models in Medicine and Biology (CEDEME) of the Federal 
University of São Paulo – Escola Paulista de Medicina 
(UNIFESP-EPM). This project received approval in advance 
from the ethics and research committee of the Federal 
University of São Paulo.
The animals were transported to the Histology and 
Structural Biology Biotery of the Morphology Department 
of UNIFESP-EPM, where they were confined to plastic 
cages that were 45 x 30 x 15 cm each in length, width, and 
height, respectively, and had lids made of metal grids. The 
rats were fed ad libitum. Room temperature was maintained 
at 22°C and artificial lighting was obtained with fluorescent 
lamps (a 40-watt-daylight Phillips model). The animals 
were maintained on a standard diet, free from any soybean 
compounds, and were provided tap water ad libitum.
Rat Endometriosis Induced by Uterine Autotransplan-
tation and Laparotomy
The endometriosis model was generated using female 
rats with normal estrous cycle maintained on a schedule of 527
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14 hours of light and 10 hours of dark during the experiment. 
The guidelines approved by the local institution for the care 
and use of the animals were followed. 
The technique was previously described in detail,12 
following the protocol described by Jones.15 Briefly, at the 
time of surgery, the animals were anesthetized with xylazine 
(20 mg/kg) and ketamine (100 mg/kg) and their abdomen 
was shaved; they were submitted to sterile preparation, 
and opened with a 1.5-cm lower mid-line incision. A 
cranial segment from the left uterine horn, 4-cm long, was 
resected. Adequate hemostasis was performed with 6/0 
nylon suture. The uterine segment was promptly immersed   
in sterile isotonic saline at 4oC, opened by longitudinal 
incision and fragmented into 5-mm square pieces. Two 
such uterine pieces were then fixed with 6/0 nylon suture 
to the abdominal wall on blood vessels, next to the median 
suture. The tissues were continuously irrigated with sterile 
isotonic saline to avoid desiccation. The abdominal incision 
was then closed in two layers using 3/0 polyglycolic acid 
threads for the muscle and abdominal fascia, and 3/0 silk 
threads for skin closure. No treatment was given during the 
postoperative period. 
All  animals  were  subjected  to  daily  vaginal 
smears to observe the estrous cycle. Four weeks after 
autotransplantation, a second laparotomy was performed in 
order to measure the sizes (length and width) of implants 
and to ovariectomize the rats during the proestrus phase 
(baseline). The rats with unsuccessful induction or irregular 
estrus cycle were excluded (n = 20). Three weeks later 
(time by which the atrophy of the implants was expected 
to occur), all animals (n=120) were randomly divided into 
six treatment groups: GI - propylenoglycol (vehicle); GII – 
17β-estradiol (50 µg/kg); GIII – 17β-estradiol (10 µg/kg); 
GIV – gestrinone (0.25 mg/kg); GV – 17β-estradiol (50 
µg/kg) with gestrinone (0.25 mg/kg); GVI – 17β-estradiol 
(10 µg/kg) with gestrinone (0.25 mg/kg). The drugs were 
given subcutaneously. Gestrinone was administered every 
48 hours. After a 24-day treatment period, the animals were 
sacrificed; the implanted peritoneal tissue was measured and 
collected along with abdominal muscle. The material was 
sectioned, fixed and processed for study by light microscopy. 
During microscopic evaluation, the investigator was blinded 
to the status of the previous growth of the implants and the 
treatment groups.
Light Microscopy Analysis
The tissue samples from the implanted area were fixed 
with 10% buffered formalin and, after routine dehydration, 
were embedded in paraffin. Sections (5 µm thick) were 
stained with hematoxylin and eosin (HE) and Masson’s 
trichrome; we used a light microscope (Axiolab, Carl Zeiss) 
under 100- to 400-fold magnification that was attached to 
an image capturing system (Axionvision, Carl Zeiss). The 
morphometric analyses were done to determine the effect 
of drugs on the glandular epithelial thickness, number of 
glands, leukocyte infiltration and extent of mitosis. 
The average value of the morphological analysis of each 
parameter was calculated from data of eight endometrial 
implant sections of each animal. The endometrial thickness 
index (ETI) was calculated using the formula: ETI = 2A/(P1 
+ P2). 25 The number of glands and leukocytes was evaluated 
using the Weibel chamber of 25 hits. For each animal, 
40 microscopic fields were analyzed using a 100x-400x 
objective. The mitosis countings were based on the number 
of typical mitoses in 1.000 epithelial cells per section. The 
averages of endometrial glands, leukocytes and mitosis were 
determined by counting all structures of every uterine cross-
section. Two independent investigators measured the total 
uterine and endometrial areas on two separate occasions.
Statistical analysis
Results were analyzed by one-way analysis of variance 
and the Tukey-Kramer multiple comparisons test, using 2.01 
version GraphPad InStat software. The differences were 
considered statistically significant when P<0.05. The paired 
Student’s t-test was also used for comparing the baseline 
(proestrus phase) with the treatment period data.
RESULTS
Implant area
The areas of implants were calculated in all animals 
before ovariectomy and after treatment, except for GI (Table 
1). In this group, no fragment of the implanted endometrium 
could be measured after treatment because of implant 
atrophy. The identification of the implant in GI was based 
upon the suture threads at the end of the experiment. The 
mean area of GII after treatment (high dose of estrogen) 
presented the highest values (p<0.01) of all groups. 
However, the GII size was similar to baseline (during the 
proestrus phase). The GIII, GIV, GV and GVI areas were 
lower than the respective baseline areas. The rat weights are 
summarized in Table 1. There were no weight differences 
among the groups in baseline versus after the treatment.
Light Microscopy Analysis
Histopathologically, the GI implants showed only 
connective tissue and cells with different shapes. The cells 528
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presented picnotic and heterochromatic nuclei in close 
contact with skeletal muscle fibers. No endometrial glands 
were identified. Table 2 summarizes the morphometric 
results. The high dose of estrogen group (GII) presented 
more well-developed endometrial implants than did the 
other groups.
DISCUSSION
Consistent with other studies, the macroscopic and 
microscopic results in vehicle- and estrogen-treated 
groups confirmed the hormone-dependent nature of the 
experimental implants.6-12 The low dose of estrogen did 
not macroscopically stimulate growth of the implants. 
However, there was evidence of estrogenic action upon 
light microscopy examination, namely an increase in 
endometrial glands, leukocyte infiltration and mitosis. In 
addition, gestrinone antagonized both doses of estrogen 
in ovariectomized rats. Although gestrinone and estrogen 
are steroids that may affect body weight,26 we did not find 
significant differences in weight among our groups.
There  is  a  small  incidence  of  endometriosis  in 
postmenopausal women, and only 2–4% of the laparoscopies 
of patients with endometriosis are performed in the 
postmenopausal period.27 Only a few investigations have 
examined the incidence of endometriosis in postmenopausal 
women and the relationship of the disease with hormonal 
replacement. Controlled post-menopausal endometriosis 
studies, as well as studies of the course of the disease under 
hormonal replacement conditions, are very difficult to carry 
out. Therefore, the rat experimental model is important 
for analyzing the estrogen and gestrinone effects on 
endometrial implants. Overall, this study demonstrated many 
morphological features of this model that may be useful for 
investigation of endometriosis.13
Some studies have demonstrated implant proliferation 
with estrogen treatment in ovariectomized rats.10-12 However, 
much of the discussion on the use of hormone replacement 
refers to what might be the minimal dose for obtaining 
benefits. In fact, many authors report that a low-dose 
estrogen replacement would have advantages with minimum 
side effects or complications in contrast to the classic 
estrogen replacement therapy. Nevertheless, this low-dose 
estrogen protocol is controversial.28,29 To address this issue, 
a previous study (data not shown) in our laboratory used a 
conventional dose of estrogen dose in the same experiments. 
Macroscopically, this higher dose produced endometrial 
implant growth and development, similar to what is seen 
in proestrus phase (high estrogen levels during the estrous 
cycle). The low-dose estrogen treatment during the first 
month presented lower stimulation of the endometrial 
implants than did the metaestrus phase (low estrogen 
levels). In this study, the low dose showed microscopic 
signals of endometrial implant proliferation (Table 1). This 
is important since many authors have suggested that one-
half the usual dose of estrogen hormone therapy could be 
safe for maintaining bone mass with minimum endometrial 
proliferation.30–32 
Table 1 - Rat weight and implant area of the endometrial implants (mean + S.E.M.) before ovariectomy (baseline) and after 
treatment
 
GI GII GIII GIV GV GVI
RT IA RT IA RT IA RT IA RT IA RT IA
Baseline 219.6 
± 19.2
32.8 
± 2.5
221.3
± 22.8
29.2 
± 2.6
230.2 
± 11.9
33.5 
± 4.1
213.6 
± 29.8
33.1 
± 2.8
239.6 
± 31.4
28.9 
± 4.2
219.6 
± 15.8
31.1 
± 2.7
After treat-
ment
220.5 
± 33.6
* 229.1 
± 24.7
34.9 
± 3.6a
211.5 
± 29.1
6.9 
± 2.9 b
225.5 
± 29.9
3.5 
± 1.5 b
232.5 
± 37.7
4.4 
± 1.5 b
231.5 
± 23.6
4.0 
± 1.3 b
RT = Rat weight (g); IA = Implant area (mm2); * = atrophic implants, only recognized by the surgical nylons. a) p<0.01 compared to GIII, GIV, GV and 
GVI after treatment; b) p<0.01 compared to baseline
Table 2 - Morphometric analyses of the endometrial implants after treatment
Implant area (mm2)
GI GII GIII GIV GV GVI
Glandular epithelial Thickness (µm) NM 16.3 ±0.5a 10.2 ± 0.6 8.6 ± 0.6 10.1 ± 0.8 9.1 ± 0.4
Endometrial glands (n) NM 88.1± 3.8a 22.9 ± 3.1b 11.2 ± 0.8 16.5 ± 0.8 10.7 ± 1.1
Leukocytes (n) NM 30.1± 2.3a 11.4 ± 1.4b 2.1 ± 0.4 4.5 ± 1.3 2.0 ± 0.6
Mitosis figure (10-3) NM 26 ± 2a 12 ± 1b 3 ± 1 5 ± 1 1 ± 1
NM = non measured; a) p<0.01 compared to other groups; b) p<0.05 compared to GIV, GV and GVI529
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Anti-estrogenic effects have been observed with 
gestrinone.33 In addition, this study showed an immunological 
effect not previously described for gestrinone. The effect 
of gestrinone may be paradoxical and may be similar to 
that described for tamoxifen by Kadaba and Simpson.34 
According to this hypothesis and as supported by our 
results, gestrinone could exert an anti-estrogenic effect when 
estrogens are present,35 but a partial agonistic effect in the 
absence of endogenous estrogens.36 This result was shown 
in our study by the macroscopic implant proliferation. The 
growth of endometrial peritoneal implants was impaired by 
about 50% in rats bearing intact ovaries.24 The hormonal 
conditions of the animals we used were diverse, since we 
used oophorectomized rats, thereby taking advantage of the 
absence of ovarian steroids which could influence the effect 
of gestrinone on endometrial growth. In addition, gestrinone 
antagonized both estrogen doses in our study. This result 
suggests that estrogen in combination with gestrinone may 
constitute an alternative treatment for postmenopausal 
women with endometriosis. However, its side-effects make 
it unsuitable for long-term use in humans.37
Gestrinone effectively antagonized the effects of estrogen 
on the implant viability in a rat model of endometriosis. This 
suggests that gestrinone could possibly produce a similar 
effect in humans, but we must keep in mind that the present 
results cannot be directly extrapolated to postmenopausal 
women.
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